Summary:
EndGenitor Technologies, Inc.’s strategy is to rapidly commercialize adult stem cell products for sale to researchers in industry and academia. As it grows its market presence and diversifies its product lines, EndGenitor expects to launch proprietary novel stem cell therapeutics for the treatment of debilitating chronic degenerative diseases. The company is solely focusing on commercializing cell products from adult tissues that are free from any ethical controversy.
Visit EndGenitor Technologies, Inc..

Description (Web site quote):
EndGenitor has licensed (from Indiana University Research & Technology Corporation) technology relating to proprietary, novel, and highly proliferative stem cell populations that mature into the lining of new blood vessels. This technology is patent pending. EndGenitor scientists are also engaged in exciting research which could lead to novel methods for stimulating and promoting blood vessel formation and growth.
Visit EndGenitor Technologies, Inc..